To analyze the role of PAI-1 (plasminogen activator inhibitor 1) in endometriotic lesion growth, we studied the effect of PAI-1 inhibition by PAI-039 using a homologous mouse model of endometriosis that allows noninvasive monitoring. Endometrial tissue from donor mice was collected, labeled with mCherry adenovirus, and implanted into a subcutaneous pocket on the ventral abdomen of recipient mice. Seven days after transplantation, mice were randomly allocated in two groups and treated once daily for 2 weeks with either vehicle (control group) or PAI-1 inhibitor (PAI-039 group). Endometriotic lesion size generated in recipient mice was monitored by mCherry signal. Animals were euthanized 21 days after endometrial tissue implantation and endometriotic lesions were harvested for fibrin deposit and vascularization analyses. Collagen content was also examined to determine the overall effects of proteolysis on extracellular matrix degradation. We demonstrated that endometriotic lesions generated in recipient mice from both groups presented characteristics typical of human endometriotic lesions. We observed a significant decrease in fluorescence signal in endometriotic lesions from the PAI-039 group at the beginning of the treatment correlated with a decrease in endometriotic lesion size. PAI-1 inhibition significantly decreased lesion cell proliferation. In addition, endometriotic lesions from the PAI-1 inhibition group showed a decreased percentage of neovascularization as well as fibrin deposits. However, the density and distribution of collagen were not affected by PAI-039. Our results suggest that in vivo inhibition of PAI-1 by PAI-039 may be a useful strategy to reduce endometriotic lesion size by blocking angiogenesis.
Introduction
Endometriosis is an estrogen-dependent chronic disorder characterized by implantation of functional endometrium outside the uterine cavity, leading to chronic pelvic pain and infertility [1] . This disease is highly heterogeneous in presentation, pathology, and clinical course. Unfortunately, endometriosis has a low response rate to current medical [2, 3] and surgical treatments (which often have serious side effects) and a frequent recurrence after treatment [4] . There is thus a critical need to develop an efficient treatment to eliminate endometriotic lesions long term with minimal side effects.
A previous study carried out by our group assessed the effects of quinagoline (dopamine receptor-2 agonist) in patients with endometriosis and demonstrated that quinagoline reduces endometriotic lesions by interfering with angiogenesis, enhancing fibrinolysis, and reducing inflammation [4, 5] . In addition, we determined that Serpine-1, the gene encoding plasminogen activator inhibitor 1 (PAI-1), was the most downregulated gene in lesions undergoing regression in quinagoline-treated mice [5] .
PAI-1 is classically known as the main modulator of fibrinolysis, a physiological process aimed at preventing/disrupting the formation of blood clots. The conversion of plasminogen to its active form plasmin, the enzyme responsible for dissolving the fibrin in the clots, is catalyzed by tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). Once the clot has been dissolved and fibrinolysis is no longer necessary, PAI-1 inhibits the conversion of plasminogen to plasmin by blocking the proteolytic activity of tPA and uPA [6, 7] . Thus, a decrease or increase in PAI-1 levels is associated with a hyper-or hypo-fibrinolytic state, respectively [8, 9] . In addition, PAI-1 can also regulate (through the modulation of plasmin proteolytic activity) extracellular matrix (ECM) remodeling and angiogenesis. Indeed, under certain circumstances, plasmin may mediate the activation of matrix metalloproteinases (MMPs), leading to the degradation of collagen, the main component of the ECM [10] [11] [12] . Degradation of the ECM is required to initiate angiogenesis and migration of cells during invasion, a process in which cells detach, proliferate, and drift to colonize surrounding tissues [13] . PAI-1 also modulates angiogenesis via plasmin-independent mechanisms through interaction with Vitronectin and αv5β3 downstream of the VEGFR2 signaling pathways [9] .
However, in vitro studies suggest that PAI-1 can exert both antiand proangiogenic actions. On one hand, antiangiogenic effects characterized by reduced motility, impaired migration, and apoptosis of neovessels have been reported in response to excessive proteolysis promoted by a sustained blockade of PAI-1 activity [14] [15] [16] . On the other hand, promoting proteolysis by interfering with PAI-1 has been reported to enhance sprouting of neovessels and invasiveness of different cell types [17, 18] . By these means, PAI-1 modulates physiological processes such as embryo invasion or placentation [19] as well as pathological processes such as tumor invasion and metastasis [20] .
Several studies have described the role of PAI-1 in cancer cells' ability to invade surrounding tissues and contribute to their deregulated growth and increased angiogenesis and demonstrated that PAI-1 is overexpressed in several tumor types [21] [22] [23] . Regression of tumors is associated with decreased expression of PAI-1, suggesting that this molecule is a predictor of tumor progression [24] . A previous study in PAI-1 deficient mice showed impaired invasiveness and angiogenesis of tumor cells that was rescued by exogenous administration of PAI-1 [14] . A later study by the same group proposed that an absence of PAI-1 inhibited tumor vascularization by promoting excessive plasmin-mediated proteolysis [25] . Subsequently, pharmacological administration of PAI-039, a potent and selective oral inhibitor of PAI-1 free of side effects even when assayed at doses several fold higher than those required to achieve EC50 [26] , was shown to mimic the antiangiogenic effects of PAI-1 deficiency in tumors engrafted in wild type animals [16] . Endometriotic and cancer lesions share the ability to invade surrounding tissues and the presence of somatic mutations [27] favoring deregulated growth and aberrantly increased angiogenesis [28, 29] . Previous studies have demonstrated that PAI-1 is overexpressed in endometriosis, just like it is in cancer [30] . In this regard, some of this studies suggested that this overexpression prevents uPA-mediated proteolytic enhancement of migration and angiogenesis [30] whilst other studies propose an opposite view in which PAI-1 overexpression promotes survival and growth of lesions by enhancing angiogenesis and migration [31, 32] . However, there are no functional in vitro or in vivo studies that provide a clear application of PAI-1 activity in treating endometriosis.
Based on these observations and the empirical assumption that PAI-1 protects pathological angiogenesis from excessive proteolysis in tumors and endometriosis, we hypothesized that sustained pharmacological inhibition of PAI-1 by PAI-039 might exacerbate the proteolytic actions of plasmin, inducing antiangiogenic actions in ectopic endometrium, which would be reflected in a reduction of lesion size. 
Materials and methods

Animals
Animal model of endometriosis
A homologous immunocompetent mouse model of endometriosis recently developed by our group [33] was employed to noninvasively assess the effects of PAI-039 treatment on lesion size. Briefly, uteri from 42 donor mice were decidualized using our optimized decidualization protocol described in Table 1 , which was previously described by our group [33] . Subsequently, decidualized endometrial tissue was collected from donor mice by gently squeezing each uterine horn with the back of a pair of curved forceps. In order to fluorescently label endometrial tissue, it was labeled using the adenoviral transfection described previously by our group [33, 34] . twice in phosphate-buffered solution (Biowest), and fluorescence was observed in the red channel (568 nm) with the use of an inverted microscope (Eclipse; Nikon). In our previous study, we demonstrated by an immunofluorescence technique using mCherry antibody, a labeling efficiency of 23.04% [32] , which is considered a high labeling efficiency using adenoviral particles, considering that adenoviruses penetrate only the outer layers of the endometrial fragments. Subsequently, one lesion in each mouse was generated by implanting mCherry-labeled endometrial fragments from three different donor mice into a subcutaneous pocket on the ventral abdomen of one recipient mouse with intact ovaries, considering the implantation day as day 0.
Pharmacological interventions
One week after mCherry-labeled endometrial tissue implantation, the recipient animals (n = 14) were subdivided into two groups. Mice were treated once daily by oral gavage with 100 μl of saline containing 20% DMSO, the PAI-039 vehicle (control group; n = 7/group), or 10 mg/kg of PAI-039 (PAI-039 group; n = 7/group). The PAI-1 dose was chosen based on its reported optimal profibrinolytic activity and lack of associated bleeding effects in animal studies [15, 35] . Mouse heath was monitored daily, evaluating for symptoms such as attitude (lethargic, aggressive, etc.), porphyria stains, posture, movements, and weight loss. Neither symptoms of dolor or disease nor weight loss were registered.
Noninvasive fluorescent monitoring
Endometriotic lesions generated in recipient animals from mCherrylabeled endometrial tissue were monitored over time with the Carestream In Vivo FX-PRO (Bruker, Madrid, Spain) and associated software coupled to an isoflurane gas anesthesia machine (XG-8 Gas Anesthesia System; Xenogen). For imaging, the area around the transplantation site was shaved to avoid signal masking caused by white hair autofluorescence and anesthetized mice were placed on a black platform. Immunofluorescence images were acquired by an excitation/emission pair filter set at 550 and 610 nm, respectively. Fluorescence was monitored beginning the day after the labeled fragments were implanted in recipient mice and the process was repeated twice weekly for 2 weeks.
Quantification of noninvasive fluorescent images
To estimate lesion size, a quantitative analysis of fluorescent regions of interest was performed using Image J software (NIH, Bethesda, MD), as previously described [33] . Fluorescence intensity was determined by the formula [Base (threshold fluorescence area) × Height (average fluorescence intensity)]. Lesion sizes for each mouse and time point were normalized to the size measured at the time point of maximum fluorescence intensity (usually on day 0 after transplantation) and expressed as the lesion size/initial lesion size ratio (%).
Recovery and preprocessing of lesions
Mice were euthanized 21 days after endometrial tissue implantation (taking into account 1 week to establish implant and 2 weeks of PAI-039 treatment). The peritoneal cavity was accessed and a visual examination was performed. Lesions were recovered, fixed in 4% neutral-buffered formalin O/N at 4
• C, embedded in paraffin, and cut into 4-μm sections for histological, immunohistochemical, and immunofluorescent characterization.
Immunohistological characterization of lesions
The presence of gland-like structures mimicking human eutopic and ectopic endometrial tissue was confirmed with hematoxylineosin staining and immunohistochemical staining using a rabbit anti-mouse cytokeratin (Dako) Negative controls were incubated without primary antibody. Subsequently, in all cases, sections were incubated with the appropriate secondary biotinylated antibody for each primary antibody (Vector Laboratories, Burlingame, CA) 1:1000, for 30 min at RT followed by treatment with the ABC kit (Vector Laboratories). The color modification reaction was performed with DAB (Vector Laboratories), and signals were visualized with a Leica DMI 3000B (Leica Microsystems Inc).
Evaluation of angiogenesis and cell proliferation
Vascularization of the endometriotic lesions was assessed by immunofluorescence for alpha-smooth muscle actin (α-SMA) (SigmaAldrich, St. Louis, USA) (1:200, 30 min at RT) in combination with fluorescein-labeled Griffonia simplicifolia isolectin B4 (IB4) (Vector laboratories, Burlingame, CA) (1:50, O/N at 4
• C) to detect the presence of mature (IB4+/α-SMA+) and immature (IB4+/α-SMA-) vessels, as previously described [33] . Negative controls were incubated without primary antibody. Images were obtained with a Leica DMI 3000B (Leica Microsystems Inc). Cell proliferation was detected by staining for Ki-67, as previously described [36] .
Evaluation of fibrinolysis and proteolysis
Fibrin and collagen were quantified to assess the extent of fibrinolysis and ECM degradation in treated and control lesions. Fibrin deposits were visualized by incubating slides with rabbit anti-fibrin (1:250 dilution, Abcam) O/N at 4
• C followed by a biotinylated antirabbit (1:750 dilution, Vector lab) secondary antibody for 30 min at RT. Staining was visualized with ABC kits using DAB as a substrate. Masson trichrome was used to define collagen deposition according to the manufacturer's instructions (Sigma-Aldrich). In
Masson trichrome, collagen deposits stain blue, while nuclei and cytoplasm stain red/pink.
Quantification of histological, immunohistochemical, and immunofluorescent staining
The two largest cross sections obtained from each lesion were considered representative of the sample. Four random high-power fields were photographed per cross section. Therefore, a total of eight images (1 implant × 2 cross sections × 4 high-power fields) per mouse (i.e. 56 images per group) were used to measure each parameter of interest. Histological, immunohistochemical, and immunofluorescent staining were assessed by Image Proplus (Media Cybernetics, Warrendale, PA), as previously described [35] . The presence of leucocytes and macrophages, vascularization, mature and immature vessels, and fibrin and collagen content were expressed as a function of the % of the stained area of interest, while the cellular proliferation was expressed as no of Ki67 positive cells.
Statistics
Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS, Inc). Data were expressed as the mean ± SEM. Nonparametric Mann-Whitney tests were used to compare differences in lesion size, vascularization, vascularization profiles, proliferation, and fibrin or collagen deposits between groups. Significance was defined as P < 0.05.
Results
Endometriotic lesion size determination
Size determination of endometriotic lesions generated in recipient mice was performed by in vivo monitoring using fluorescencelifetime imaging. We observed that the amount of fluorescence provided by mCherry-labeled endometrial tissue implanted in recipient mice was similar at the beginning of the experiment (from day 0 to day 8) in both groups ( Figure 1A ). Four days after the tissue implantation, a uniform reduction in the fluorescence signal was observed in both groups and continued until the end of the experiment, as expected in accordance with the episomal and transient expression of adenoviral particles ( Figure 1A ). However, in the PAI-039 group, this reduction exhibited a significant decay in signal on day 12 (with day 7 as the beginning of PAI-039 treatment), while the decay remained uniform in the control group ( Figure 1A and B). As of that moment, the difference in decay rates between both PAI-039 and the control group was statistically significant (P-value < 0.05) ( Figure 1B) . At the end of the study period, after 2 weeks of treatment, the fluorescent signal intensity was reduced to 56.1 ± 9.5% and 29.2 ± 5.2% for the control and PAI-039 groups, respectively, compared to the point at which signal intensity was maximal (100%) on day 0 after the implantation ( Figure 1B ). This significant reduction of fluorescence signal in the PAI-039 group in comparison with the control group likely reflects a decrease in endometriotic lesion size. However, PAI-039 treatment was not able to completely eliminate endometriotic lesions, which were macroscopically visible in both groups when mice were euthanized at day 21 ( Figure 2A ). During necropsy, the peritoneal cavity was accessed and a visual examination was performed. Uteri, ovaries, and other visceral organs showed a healthy appearance in all of the mice.
Characterization of induced endometriotic lesions
To corroborate that endometriotic lesions generated in recipient mice mimic human eutopic and ectopic endometrial tissue even though endometrial tissue implanted comes from donor mice, hematoxylineosin staining (Supplemental Figure S1 ) and immunohistochemistry were carried out. The presence of gland-like structures was confirmed with immunohistochemical staining of cytokeratin, a protein found in the intracytoplasmic cytoskeleton of epithelial tissue. We observed cytokeratin staining, and thereby, the presence of epithelial cells organized into glands resembling human endometrial tissue in both the control and PAI-039 groups ( Figure 2B ). The number of glands was similar in both groups, indicating that PAI-039 treatment did not affect gland formation, which is characteristic of human endometriotic lesions.
Since human endometriosis is associated with local inflammation leading to increases in the number of macrophages and leukocytes present in the lesions, we verified the presence of these immune cells in the endometriotic lesions generated in recipient mice. We observed a homogeneous distribution and similar presence of macrophages ( Figure 2C and E) and leukocytes ( Figure 2D and F) in lesions from both groups, mimicking the local inflammation characteristics typical of human endometriosis.
Evaluation of vascularization and proliferation
Vascularization profiles were assessed to characterize the angiogenic status of endometriotic lesions generated in recipient mice. We observed that endometriotic lesions from the PAI-039 group presented an appreciable but not statistically significant decrease in the percentage of total vascularized area compared to the control group (15.4 ± 4.8% vs 25.4 ± 3.6%, respectively) ( Figure 3A and B) . However, the PAI-039 group showed a statistically significant decrease in immature vessels (IB4+/αSMA-) compared to the control group, in which immature vessels were predominant ( Figure 3C ). Although the area occupied by mature vessels in endometriotic lesions was similar in both groups, the area of immature vessels ( Figure 3C ) was significantly lower in endometriotic lesions generated in recipient mice from the PAI-039 group.
To determinate whether PAI-039 treatment inhibits cell proliferation and thereby endometriotic lesion growth, we assessed cell proliferation in generated lesions in recipient mice and observed that proliferating cells were significantly lower in the PAI-039 group compared to lesions from the control group (38.2 ± 8.3% vs 72.9 ± 15.9%, respectively) ( Figure 3D and E) , indicating a reduction in cell proliferation with PAI-039 treatment.
Evaluation of extracellular matrix density
Fibrin and collagen content were measured to assess the extent of fibrinolysis and degradation of ECM induced by pharmacological inhibition of PAI-1 using PAI-039. We observed fibrin staining in focal deposits surrounding the endometriotic lesions from control group mice (10.5 ± 1.2%). In contrast, very few fibrin deposits were detected around lesions from PAI-039 mice (1.0 ± 0.7%) ( Figure 4A ), being this reduction in fibrin deposits statistically significant ( Figure 4B ).
To evaluate degradation of ECM, collagen deposits were observed in endometriotic lesions from recipient mice in both groups. We observed collagen deposits surrounding the glands and the periphery of the lesions in both groups ( Figure 4C ). No statistically significant differences were detected in collagen stained area between PAI-039 and control group (12.5 ± 3.0% and 14.0 ± 3.2% vs, respectively) ( Figure 4D ).
Discussion
The goal of this study was to observe whether PAI-039 (a PAI-1 inhibitor) administration decreases endometriotic lesion size through fibrinolysis and/or angiogenesis inhibition, using a noninvasive immunocompetent mouse model of endometriosis that presents immune cells, such as macrophages, that release fibrinolytic factors that could be implicated in endometriosis development. Several studies showed that PAI-1 is overexpressed in endometriotic lesions [31, 32, 37] , and we previously reported that Serpine-1, the gene encoding PAI-1, is significantly downregulated in human endometriotic lesions undergoing regression [28] , resulting in an inhibition of PAI-1 expression. This finding suggested that inhibition of PAI-1 could protect pathological tissue from antiangiogenic effects due to excessive proteolysis, interfering with angiogenic-dependent growth of lesions and thus offering a potential therapeutic tool for endometriosis.
Here, we observed a reduction in the fluorescence signal in both control and PAI-039 groups, indicating that m-Cherry labeling decays overtime. This decrease might be explained by the episomal expression of the adenovirus [34] . However, in the PAI-039 group, this mCherry signal reduction exhibited a higher decrease on day 12 (5 days after initiating the treatment) in comparison with control group, which was maintained over the time course. In the absence of functional experiments in appropriate models of endometriosis, previous studies of PAI-1 assessed its effects on cancer, which has pathological similarities to endometriosis [30] . Based on those findings PAI-1 is expected to be repressed initially to enhance plasmindependent degradation of ECM, which is necessary for the migration of invading neovessels [38] , and subsequently, overexpressed to invert the process because an appropriate ECM scaffold is required to allow invading tissues to settle and grow. However, PAI-1 overexpression is commonly found in human tumors associated with a worse prognosis [39] , suggesting that PAI-1 overexpression does not prevent angiogenesis in tumors in vivo but most likely accomplishes the angiogenic demands of pathological tissue. Therefore, PAI-1 could play a similar role in the control of angiogenesis in both tumors and endometriotic lesions. In this regard, the mCherry signal decrease in our study by PAI-039 administration in late stages (7 days after the tissue implantation) suggested a reduction in cell proliferation and supports the hypothesis that PAI-1 plays a significant role in promoting lesion growth and survival. The vascularization analysis in endometriotic lesions showed a decrease in immature vessels in the PAI-039 group, while the level of mature vessels was similar to that of the control group, suggesting that PAI-1 inhibition dramatically decreased neovascularization. This inhibition in neovascularization supports the hypothesis that PAI-1 inhibition plays an antiangiogenic role, inhibiting immature vessel formation but not mature vessels, which are less sensitive to its inhibitory actions [29] . Decreases in neovascularization in the PAI-039 group were associated with a significant decrease in fibrin content, indicating an increase in fibrinolysis. Therefore, the dramatic decrease in fibrin content in the PAI-039 group suggests the inhibitory activity of PAI-1 on the protease activity of uPA in activating plasmin is appropriately blocked, which is essential to fibrinolysis [6, 7] . Based on this finding, we suggest that PAI-1 inhibition enhances fibrinolysis and inhibits neovascularization, explaining the antiangiogenic effects observed. In agreement with this interpretation, excessive proteolysis due to PAI-1 blockade has been shown in vitro to decrease migration and neovascularization [40] . In addition, another study suggested that this anti-angiogenic effect is expected to be associated with the degradation of ECM [14] . Our observations about fibrin degradation in our in vivo endometriosis mouse model agree with such predictions.
In addition to fibrin, plasmin might degrade other components of the ECM, such as collagen, which is the main component of ECM. For this reason, we also analyzed collagen degradation to evaluate whether proteolysis had been extended to dramatically compromise lesion survival. We did not detect any significant difference in collagen deposits between groups. However, this did not mean that plasmin activity was not enhanced in response to PAI-1 inhibition, which is evident by the observed enhancement of fibrinolysis. The results of fibrin degradation, but unaffected collagen degradation, in the presence of active plasmin suggest that natural metalloprotease (MMP) inhibitors might prevent collagen proteolysis in ECM [41] , implying a selective induction of proteolytic effects in the ECM in response to PAI-1 blockade.
Based on these findings, we suggest that PAI-1 inhibition promotes a moderate increase in proteolysis, which leads to significant inhibition of angiogenesis that reduces lesion growth but not enough to compromise its survival. However, it would be premature to propose PAI-1 inhibition as a therapy to endometriosis treatment in humans, especially because PAI-1 inhibition presents controversy regarding fertility. Several studies suggested that PAI-1 inhibitor treatment is contraindicated in pregnant women, due to the possibility of hemorrhages and increased risk of miscarriage [42] . Meanwhile, other recent meta-analysis studies have shown no evidence of teratogenic or abortive effects in these women [43] . To clarify its clinical utility, further studies are needed to address the appropriateness of PAI-1 blockade therapy and its mechanism of action. In particular, PAI-1 blockade therapy alone or in combination therapies should be assessed for its potential to eliminate endometriotic lesions (since PAI-1 inhibition alone did not decrease growth lesion enough to compromise its survival), while avoiding side effects on endometrium/ovary that could affect fertility. In addition, studies on the inhibition of plasmin and PAI-1 in endometriotic lesions would be required to demonstrate that PAI-1 actions are mediated by proteolysis induction.
In summary, our findings suggest that PAI-1 overexpression in endometriotic lesions feeds into the angiogenic demands of pathological tissue and/or overrides a protection mechanism that regulates excessive proteolysis, which takes place during surrounding tissue invasion. In line with this hypothesis, our experiments showed that blocking PAI-1 inhibits endometriotic lesion growth by interfering with proteolysis-driven angiogenesis. The effects observed in lesion size in response to PAI-039 are promising and warrant subsequent efforts to establish specific nontoxic therapies targeting PAI-1.
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Supplementary data are available at BIOLRE online. Figure S1 . Body weight monitoring during the experiment. Neither weight loss nor symptoms of dolor or disease were registered after PAI-039 treatment compared to control mice.
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